Please log in
You must be logged in to send the contact request.
Manage stand orders
Select Option
Sound Wave Innovation CO., LTD.
Ueno Building F6(c-5), 1-9-10, Horidome- Cho Nihonbashi, Chuo-ku,
103-0012
Tokyo
Japan
Japan
Submit your contact details
Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
Your name, phone number, and e-mail address are subject to the submission of personal data. Messe Düsseldorf GmbH expressly points out that for a data transmission into third countries, for which no adequacy decision of the EU-commission is on hand certifying an adequate level of protection of personal data, it is not ensured that there are appropriate safeguards for the protection of personal data on hand.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
This company is co-exhibitor of
JETRO (Japan External Trade Organization)
Contact
Our range of products
Product categories
- 01 Electromedical equipment / medical technology
- 01.03 Surgery devices, endoscopy devices
- 01.03.12 Other surgical instruments and products
Other surgical instruments and products
- 01 Electromedical equipment / medical technology
- 01.04 Therapy and physical medicine
- 01.04.08 Ultrasonic therapy equipment
Ultrasonic therapy equipment
- 01 Electromedical equipment / medical technology
- 01.04 Therapy and physical medicine
- 01.04.09 Other equipment for therapy and physical medicine
Other equipment for therapy and physical medicine
Our products
Product category: Other equipment for therapy and physical medicine
LIPUS (Low Intensity Pulsed Ultlasound)
Indications：Severe angina, dementia, etc.
LIPUS is a brand-new cutting-edge modality and less invasive modality compared to the existing treatment methods. Irradiation of low intensity pulsed ultrasonic waves(250mW, 32 waves) acts on vascular endothelial cells (Caveolin-1) and leads to upregulate both eNOS (vascular endothelial nitric oxide synthase) and VEGF (vascular endothelial growth factor). We expect LIPUS will become an excellent modality for many indications related to microcirculatory disorder.
Regarding severe angina, Prof. Shimokawa’s group developed a low-intensity extracorporeal shock wave device (SW) and that was approved by the Japanese Ministry of Health, Labor and Welfare as advanced medical treatment in 2010. However, there remained some challenges that doctors needs to be careful not to irradiate lungs and take some time to adjust the device.
LIPUS irradiates ultrasonic waves with comaprable output range of echo examinations in health examinations, so it is less invasive and significantly reduces safety risk compared to SW. Prof. Shimokawa’s group discovered LIPUS irradiation conditions that are as effective as SW, and has obtained enough evidence in both basic research and preclinical studies, and the clinical trials have been on going. LIPUS is expected to be applied to mild dementia and other microcirculatory disorder diseases, and it comes to the point only a few years before approval.
LIPUS is a brand-new cutting-edge modality and less invasive modality compared to the existing treatment methods. Irradiation of low intensity pulsed ultrasonic waves(250mW, 32 waves) acts on vascular endothelial cells (Caveolin-1) and leads to upregulate both eNOS (vascular endothelial nitric oxide synthase) and VEGF (vascular endothelial growth factor). We expect LIPUS will become an excellent modality for many indications related to microcirculatory disorder.
Regarding severe angina, Prof. Shimokawa’s group developed a low-intensity extracorporeal shock wave device (SW) and that was approved by the Japanese Ministry of Health, Labor and Welfare as advanced medical treatment in 2010. However, there remained some challenges that doctors needs to be careful not to irradiate lungs and take some time to adjust the device.
LIPUS irradiates ultrasonic waves with comaprable output range of echo examinations in health examinations, so it is less invasive and significantly reduces safety risk compared to SW. Prof. Shimokawa’s group discovered LIPUS irradiation conditions that are as effective as SW, and has obtained enough evidence in both basic research and preclinical studies, and the clinical trials have been on going. LIPUS is expected to be applied to mild dementia and other microcirculatory disorder diseases, and it comes to the point only a few years before approval.
Product category: Other equipment for therapy and physical medicine
Shock Wave Ablation Catheter System (SWCS)
Indications: Arrhythmias
The number of domestic patients with arrhythmias (ventricular tachycardia (VT) and ventricular fibrillation (Vf)) is estimated to be 5,000 to 11,000 yearly. So far radio frequency ablation catheters(RFCA) are the main existing therapy, but it has several fundamental limitations, including limited ablation depth, thrombus formation, and prolonged inflammation.
SWCS developed by Prof. Shimokawa’s group uses a non-thermal process to converge the shock wave to the arrhythmia source for treatment, so it does not cause damage to the tissue surface and surroundings due to heat, and the depth of ablation can be set larger. It could become a more effective and safer option for arrhythmias
The number of domestic patients with arrhythmias (ventricular tachycardia (VT) and ventricular fibrillation (Vf)) is estimated to be 5,000 to 11,000 yearly. So far radio frequency ablation catheters(RFCA) are the main existing therapy, but it has several fundamental limitations, including limited ablation depth, thrombus formation, and prolonged inflammation.
SWCS developed by Prof. Shimokawa’s group uses a non-thermal process to converge the shock wave to the arrhythmia source for treatment, so it does not cause damage to the tissue surface and surroundings due to heat, and the depth of ablation can be set larger. It could become a more effective and safer option for arrhythmias
About us
Company details
SWI is a therapeutic medical device startup having strong relationship with Tohoku University(Japan). Making progress on Clinical Studies of both LIPUS and SWCS (less invasive therapies) that have been developed by Professor Emeritus Hiroaki Shimokawa group, we aim to realize our innovative devices both with Tohoku University and Medical Device Company.
LIPUS(low power pulsed ultrasound)
The molecular mechanisms of the LIPUS therapy include mechano-transduction mediated by β1-integrin/caveolin-1 with resultant upregulation of endothelial NO synthase(eNOs) and vascular endothelial growth factor(VEGF). It enhaces angiogenesis in ischemic tissue and induce spontaneous improvement of microcirculatory disorder for both severe angina and mild dementia. Two pipelines are in clinical study.
SWCS(shock wave ablation catheter system)
Comparing to the ablation catheter that has been used for the treatment of arrhythmia, SWCS could treat deeper Arrhythmia source with less surface / peripheral tissues damage and less Thrombus formation.
LIPUS(low power pulsed ultrasound)
The molecular mechanisms of the LIPUS therapy include mechano-transduction mediated by β1-integrin/caveolin-1 with resultant upregulation of endothelial NO synthase(eNOs) and vascular endothelial growth factor(VEGF). It enhaces angiogenesis in ischemic tissue and induce spontaneous improvement of microcirculatory disorder for both severe angina and mild dementia. Two pipelines are in clinical study.
SWCS(shock wave ablation catheter system)
Comparing to the ablation catheter that has been used for the treatment of arrhythmia, SWCS could treat deeper Arrhythmia source with less surface / peripheral tissues damage and less Thrombus formation.
Company data
Sales volume< 1 Mio US $
Number of employees1-19
Area of businessImaging and diagnostics / medical equipment & devices